Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.Xeris Biopharma Holdings stock is taking a hit today. What’s weighing on XERS shares?Lawsuit Targets Two Pharmaceutical CompaniesThe lawsuit, filed by Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, targets unauthorized generic versions of Recorlev. The lawsuit names Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC as the ...

Ensysce Biosciences (NASDAQ:ENSC) shares are up on Friday as the company has initiated a review of strategic alternatives aimed at enhancing shareholder value.The company on Wednesday announced that its Board of Directors is exploring a range of strategic alternatives, which may include partnerships, licensing arrangements, or asset sales.The strategic review is intended to support the advancement of its proprietary technologies, specifically the TAAP and MPAR platforms.“Our technologies were designed to fu ...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET Disclosure of a transparency notification from AOC Pharma S.à r.l. Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from AOC Pharma S.à r.l., dated 24 February 2026. Notification from AOC Pharma S.à r.l. On 24 February 2026, Fagron received a transparency notification from AOC Pharma S.à r.l., informing the Company that ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) showcases a Return on Invested Capital (ROIC) of 10.34%, significantly outperforming its Weighted Average Cost of Capital (WACC) of 5.18%.Amphastar Pharmaceuticals and Syndax Pharmaceuticals demonstrate lower efficiency in capital utilization compared to Collegium, with Amphastar barely generating returns above its cost of capital.Ironwood Pharmaceuticals exhibits the highest efficiency with a ROIC of 62.21% and a WACC of 6.21%, indicating exceptional capital man ...

NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Corcept Therapeutics Incorporated (NASDAQ: CORT) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Corcept securities between October 31, 2024 and December ...

Following the pullback seen in the previous session, stocks are seeing continued weakness during trading on Friday. The major averages have all moved to the downside, with the Dow hitting its lowest intraday level in almost a month.Currently, the major averages are well off their lows of the session but remain firmly negative. The Dow is down 565.35 points or 1.1 percent at 48,933.85, the Nasdaq is down 163.05 points or 0.7 percent at 22,715.33 and the S&P 500 is down 38.61 points or 0.6 percent at 6,870.2 ...

Core Insights - Johnson & Johnson's (JNJ) stock has increased by 38.4% over the past six months, supported by a positive earnings outlook and strong fundamentals [1][8] - The stock has been trading above its 50-day and 200-day simple moving averages for over eight months, indicating a sustained uptrend [1] - J&J's Innovative Medicine segment achieved over $60 billion in sales in 2025, despite the loss of exclusivity for its product Stelara [6][8] Group 1: Financial Performance - J&J's stock has outperformed the industry, rising 47.2% in the past year compared to a 10.0% increase in the industry [21] - The company recorded three consecutive quarters of sales exceeding $15 billion in the Innovative Medicine segment [6] - J&J expects to generate around $100 billion in revenues in 2026, with sales growth anticipated in both its segments [31] Group 2: Segment Analysis - The Innovative Medicine unit's sales grew 4.1% on an organic basis in 2025, driven by key drugs like Darzalex, Erleada, and Tremfya [5][7] - The MedTech segment saw a 4.3% organic sales increase in 2025, aided by acquisitions and improvements in various business areas [13] - J&J anticipates better growth in the MedTech business in 2026, driven by new product adoption [14] Group 3: Pipeline and R&D - J&J invested over $32 billion in R&D and M&A in 2025, advancing its pipeline significantly [9][10] - The company gained approval for new products, including Inlexzoh/TAR-200 and Imaavy, which are expected to drive future growth [10] - J&J believes that 10 of its new products have the potential to deliver peak sales of $5 billion [12] Group 4: Challenges and Headwinds - J&J faces challenges from the patent loss of Stelara, which accounted for approximately 18% of the Innovative Medicine unit's sales in 2024 [16] - The company is dealing with over 73,000 lawsuits related to its talc-based products, which could impact its financials [19][20] - Sales in China are affected by the volume-based procurement (VBP) program, which is expected to continue impacting J&J in 2026 [15]

Core Insights - Jazz Pharmaceuticals has achieved a significant milestone by generating over $1 billion in annual product sales from its cannabis-derived therapy, Epidiolex, marking its entry into blockbuster territory [2][10] Group 1: Epidiolex Performance - Epidiolex generated $1.1 billion in product sales in 2025, accounting for approximately 25% of Jazz's total revenues, with a year-over-year growth of 9% driven by strong prescription demand [4][10] - The growth of Epidiolex is no longer limited to pediatric patients, with the company identifying adult patients, especially in long-term care settings, as a key growth opportunity [5] - Jazz has resolved nearly all outstanding ANDA litigations related to Epidiolex, extending patent protection into the late 2030s, which enhances revenue visibility and reduces the threat from generic competition [6][10] Group 2: Diversified Portfolio - Jazz Pharmaceuticals has a diversified biopharma portfolio that includes products in neuroscience and oncology, in addition to its cannabis-derived therapies [7] - The oxybate franchise, particularly Xywav, has become a significant growth driver, providing treatment for narcolepsy without the sodium-related warnings associated with previous formulations [8] - Oncology sales now account for over 26% of Jazz's total revenues, supported by new product launches and increasing market share [9] Group 3: Pipeline and Market Position - Despite commercial successes, Jazz has faced setbacks in its pipeline, including the discontinuation of suvecaltamide and disappointing results from a mid-stage study on JPZ150 for PTSD [12][13] - Jazz's stock has risen 11% year-to-date, outperforming the industry average of 8%, although earnings estimates present a mixed outlook for 2026 and 2027 [14][16] - Compared to pure-play cannabis companies, Jazz offers a more balanced risk profile, with recurring cash flows from its neuroscience and oncology products, while Epidiolex provides exposure to the medical cannabis market projected to exceed $130 billion by 2032 [18]

Key Takeaways Xenon reported a Q4 loss of $1.31 per share, wider than estimates, with no revenues recorded.XENE's R&D expenses rose 47% to $87.7M, driven by late-stage azetukalner studies.Xenon expects its $586M cash to fund phase III epilepsy, MDD and BPD programs into 2027.Xenon Pharmaceuticals (XENE) reported a loss of $1.31 per share for the fourth quarter of 2025, wider than the Zacks Consensus Estimate of a loss of $1.20. The company had incurred a loss of 84 cents per share in the year-ago quarter.In ...

ANI Pharmaceuticals (ANIP) reported $247.06 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 29.6%. EPS of $2.33 for the same period compares to $1.63 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $232.98 million, representing a surprise of +6.04%. The company delivered an EPS surprise of +17.32%, with the consensus EPS estimate being $1.99.While investors closely watch year-over-year changes in headline numbers -- revenue and ea ...